p62 overexpression promotes neoplastic stromal cell proliferation and is associated with the recurrence of giant cell tumor of bone

Liu,Shu; Ye,Fan; Li,Dongqi; He,Chuanchun; He,Hao; Zhang,Jing

doi:10.3892/ol.2020.11947

p62 overexpression promotes neoplastic stromal cell proliferation and is associated with the recurrence of giant cell tumor of bone

Authors:
- Shu Liu
- Fan Ye
- Dongqi Li
- Chuanchun He
- Hao He
- Jing Zhang
View Affiliations

Affiliations: Department of Orthopaedics, Bone and Soft Tissue Tumors Research Center of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118, P.R. China
Published online on: August 5, 2020 https://doi.org/10.3892/ol.2020.11947
Article Number: 86
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Giant cell tumor of bone (GCTB) is an intermediate (locally aggressive) bone tumor with a recurrence rate of >30% following surgery. GCTB recurrence is ultimately due to the proliferation of neoplastic stromal (NS) cells. However, the precise mechanism underlying the regulation of NS cell proliferation remains unknown. p62 protein is a multifunctional adaptor protein that exerts a positive role in bone tumors and metabolic bone diseases. In the present study, the mRNA and protein expression levels of p62 were detected by reverse transcription‑quantitative PCR and western blotting, respectively, in 8 paired fresh GCTB tumor tissues and adjacent normal cancellous bone tissues. The association between p62 expression level and patient prognosis was subsequently analyzed in 54 paraffin‑embedded tumor specimens by immunohistochemistry assay. NS cells were isolated from GCTB primary cell culture, and the role of p62 was evaluated using in vitro cell proliferation, migration and invasion assays. The results revealed that p62 mRNA and protein were overexpressed in tumor tissues. High p62 expression levels were significantly associated with the recurrence of GCTB (P=0.001). The patients in the high p62 expression group had shorter 5‑year recurrence‑free survival rates compared with the patients in the low p62 expression group (P<0.001). Cox regression analysis identified p62 expression as an independent prognostic indicator of the recurrence‑free survival of patients with GCTB (P<0.001). The in vitro experiments revealed that p62 downregulation inhibited NS cell proliferation, invasion and migration, and promoted apoptosis. In conclusion, it was found that p62 overexpression is associated with the recurrence of GCTB via the promotion of NS cell proliferation. Therefore, p62 could be a novel prognostic indicator, and a potential therapeutic target for GCTB.

View Figures

View References

1	Mavrogenis AF, Igoumenou VG, Megaloikonomos PD, Panagopoulos GN, Papagelopoulos PJ and Soucacos PN: Giant cell tumor of bone revisited. SICOT J. 3:542017. View Article : Google Scholar : PubMed/NCBI
2	Niu X, Zhang Q, Hao L, Ding Y, Li Y, Xu H and Liu W: Giant cell tumor of the extremity: Retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am. 94:461–467. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lüke J, Hasenfratz M, Möller P and Barth TFE: New aspects on giant cell tumor of bone. Pathologe. 39:125–131. 2018.(In German). View Article : Google Scholar : PubMed/NCBI
4	Zhou Z, Li Y, Xu L, Wang X, Chen S, Yang C and Xiao J: Biological characteristics of a novel giant cell tumor cell line derived from spine. Tumour Biol. 37:9681–9689. 2016. View Article : Google Scholar : PubMed/NCBI
5	Fan L, Yin S, Zhang E and Hu H: Role of p62 in the regulation of cell death induction. Apoptosis. 23:187–193. 2018. View Article : Google Scholar : PubMed/NCBI
6	Sánchez-Martín P, Saito T and Komatsu M: p62/SQSTM1: ‘Jack of all trades’ in health and cancer. FEBS J. 286:8–23. 2019. View Article : Google Scholar : PubMed/NCBI
7	Lu Y, Wang Q, Zhou Y, Sun L, Hu B, Xue H, Li M, Zhang K, Ren C, Duan N, et al: Overexpression of p62 is associated with poor prognosis and aggressive phenotypes in osteosarcoma. Oncol Lett. 15:9889–9895. 2018.PubMed/NCBI
8	Sha Z, Schnell HM, Ruoff K and Goldberg A: Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation. J Cell Biol. 217:1757–1776. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zhang J, Yang Z and Dong J: P62: An emerging oncotarget for osteolytic metastasis. J Bone Oncol. 5:30–37. 2016. View Article : Google Scholar : PubMed/NCBI
10	Shaw B, Burrel CL, Green D, Navarro-Martinez A, Scott D, Daroszewska A, van't Hof R, Smith L, Hargrave F, Mistry S, et al: Molecular insights into an ancient form of Paget's disease of bone. Proc Natl Acad Sci USA. 116:10463–10472. 2019. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Langer R, Neppl C, Keller MD, Schmid R, Tschan MP and Berezowska S: Expression analysis of autophagy related indicators LC3B, p62 and HMGB1 indicate an autophagy-independent negative prognostic impact of high p62 expression in pulmonary squamous cell carcinomas. Cancers (Basel). 10:2812018. View Article : Google Scholar
13	Karras P, Riveiro-Falkenbach E, Cañón E, Tejedo C, Calvo TG, Martínez-Herranz R, Alonso-Curbelo D, Cifdaloz M, Perez-Guijarro E, Gómez-López G, et al: p62/SQSTM1 fuels melanoma progression by opposing mRNA decay of a selective set of pro-metastatic factors. Cancer Cell. 35:46–63 e10. 2019. View Article : Google Scholar : PubMed/NCBI
14	Xing M, Li P, Wang X, Li J, Shi J, Qin J, Zhang X, Ma Y, Francia G and Zhang JY: Overexpression of p62/IMP2 can promote cell migration in hepatocellular carcinoma via activation of the Wnt/β-catenin pathway. Cancers (Basel). 12:72019. View Article : Google Scholar
15	Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S, Duran A, et al: p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-Initiating cells. Cancer Cell. 29:935–948. 2016. View Article : Google Scholar : PubMed/NCBI
16	Moscat J, Karin M and Diaz-Meco MT: p62 in Cancer: Signaling adaptor beyond autophagy. Cell. 167:606–609. 2016. View Article : Google Scholar : PubMed/NCBI
17	Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burhanova LA, Badrtdinova II, et al: Safety and efficacy of P62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors. Oncotarget. 8:53730–53739. 2017. View Article : Google Scholar : PubMed/NCBI
18	Singer FR: Paget's disease of bone-genetic and environmental factors. Nat Rev Endocrinol. 11:662–671. 2015. View Article : Google Scholar : PubMed/NCBI
19	Cowan RW and Singh G: Giant cell tumor of bone: A basic science perspective. Bone. 52:238–246. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lipplaa A, Dijkstra S and Gelderblom H: Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Curr Opin Oncol. 31:329–335. 2019. View Article : Google Scholar : PubMed/NCBI
21	Branstetter DG, Nelson SD, Manive JC, Blay JY, Chawla S, Thomas DM, Jun S and Jacobs I: Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 18:4415–4424. 2012. View Article : Google Scholar : PubMed/NCBI
22	Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, et al: Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumor of bone: Interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 14:901–908. 2013. View Article : Google Scholar : PubMed/NCBI
23	Mukaihara K, Suehara K, Kohsaka S, Akaike K, Tanabe T, Kubota D, Ishii M, Fujimura T, Kazuno S, Okubo T, et al: Protein expression profiling of giant cell tumors of bone treated with denosumab. PLoS One. 11:e01484012016. View Article : Google Scholar : PubMed/NCBI
24	Lau CP, Huang L, Wong KC and Kumta SM: Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connect Tissue Res. 54:439–449. 2013. View Article : Google Scholar : PubMed/NCBI